Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials

By afschroeder • October 23, 2025

Gresham G, Henry NL, Bandos H, Calsavara VF, Cecchini RS, Diniz MA, Hays RD, Luu M, Kim S, Rogatko A, Yothers G, Ganz PA, Tighiouart M. Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials. Cancer. 2025 Oct 15;131 Suppl 2:e70086. doi: 10.1002/cncr.70086. PMID: 41123586.

Tags: biostatistics, cancer clinical trials, Cedars Sinai DoM, General Internal Medicine, Hematology/Oncology, patient‐reported outcomes, Publications, toxicity, toxicity index, Treatment tolerability

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial

McDonald CM, Villa C, Soslow JH, Maharry K, Hogan N, Binks M, Berth KC, Elliott KA, Taylor M, Hor KN, Signorovich J, Henricson EK, Phan[...]

Hidden risk in normal myocardial perfusion scans: AI-detected proximal coronary calcium on CT attenuation maps improves prognosis

Zhou J, Miller RJH, Shanbhag A, Killekar A, Han D, Patel KK, Pieszko K, Yi J, Urs MK, Ramirez G, Lemley M, Kavanagh PB, Liang[...]

Correction to: Consensus and Controversies about Diagnosing GH deficiency – A Delphi Survey by the GH Research Society

Radovick S, Arlien-Søborg MC, Boguszewski MCS, Bidlingmaier M, Johannsson G, Grimberg A, Ho KKY, Biller BMK, Choong CS, Hoffman AR, Backeljauw P, Boguszewski CL, Bollerslev[...]